PRIMARY OBJECTIVES:~I. To estimate the efficacy of hypoxia inducible factor (HIF)-2 alpha inhibitor PT2385 (PT2385) as measured by radiographic response rate (by Response Assessment in Neuro-Oncology, RANO, criteria) in patients with recurrent glioblastoma.~SECONDARY OBJECTIVES:~I. To estimate the efficacy of PT2385 as measured by progression free and overall survival in patients with recurrent glioblastoma.~II. To determine the safety of oral PT2385 in patients with recurrent glioblastoma.~TERTIARY OBJECTIVES:~I. To describe the pharmacokinetic and pharmacodynamic properties of PT2385 in patients with recurrent glioblastoma.~II. To describe baseline intratumoral hypoxia using novel, advanced magnetic resonance (MR)-based neuroimaging sequences in patients with recurrent glioblastoma.~III. To explore genetic polymorphisms involved in the metabolism of PT2385.~OUTLINE:~Patients receive HIF-2 alpha inhibitor PT2385 orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed up every 2 months for 2 years and every 6 months thereafter.
This phase II trial studies how well HIF-2 alpha inhibitor PT2385 works in treating patients with recurrent glioblastoma. HIF-2 alpha inhibitor PT2385 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.